Modality
Multispecific
MOA
KRASG12Ci
Target
FGFR
Pathway
Hedgehog
GIST
Development Pipeline
Preclinical
~May 2016
→ ~Aug 2017
Phase 1
Nov 2017
→ Mar 2027
Phase 1Current
NCT06476834
2,309 pts·GIST
2017-11→2027-03·Active
2,309 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-03-2112mo awayInterim· GIST
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P1
Active
Catalysts
Interim
2027-03-21 · 12mo away
GIST
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06476834 | Phase 1 | GIST | Active | 2309 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| ALN-6288 | Alnylam | Approved | LAG-3 |